Company Overview: GSK

Upcoming Projects (GSK)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (GSK)

Investigating the phase III results from the ANCHOR clinical trials on depemokimab in chronic rhinosinusitis with nasal polyps.
Ticker: GSK
Executed On: Nov 14, 2024 at 10:00 AM EST
Discussing the results from the SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab in severe asthma
Ticker: GSK
Executed On: Sep 19, 2024 at 09:30 AM EDT
A Second Opinion: Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 20, 2024 at 02:30 PM EDT
Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 12, 2024 at 11:00 AM EDT
A Second Look: Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Sep 01, 2023 at 08:00 AM EDT
Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Aug 25, 2023 at 09:00 AM EDT
Discussing the SKYSCRAPER-01 trial of tiragolumab in Non Small Cell Lung Cancer (NSCLC) and readthrough to iTeos/GSK's belrestotug
Tickers: ITOS, GSK, RHHBY
Executed On: Jul 14, 2023 at 01:30 PM EDT
Understanding the roles TIGIT targeting drugs play in cancer immunotherapy and efficacy compared to PD-1 inhibitors
Tickers: RHHBY, MRK, GSK, BMS, RCUS
Executed On: May 05, 2023 at 04:30 PM EDT
Discussing GSK’s Daprodustat in Chronic kidney disease, ahead of the PDUFA date of 2/1/2023
Ticker: GSK
Executed On: Jan 30, 2023 at 11:00 AM EST
A Second Opinion: Looking at the topline results of the Phase 2 MISSION trial of zetomipzomib in Lupus Nephritis patients
Tickers: KZR, GSK, AUPH
Executed On: Sep 01, 2022 at 01:00 PM EDT
A discussion of DREAMM-5 Study (low-dose Blenrep + nirogacestat) in r/r Multiple myeloma
Tickers: SWTX, GSK
Executed On: May 23, 2022 at 01:30 PM EDT
A Second View: Discussing the Pneumococcal vaccine market and where a new vaccine could potentially fit in
Tickers: PFE, PCVX, GSK, MRK, Affinivax, ALPMY
Executed On: Jan 07, 2022 at 10:00 AM EST
Discussing BCMA targeted therapies in r/r multiple myeloma
Tickers: JNJ, GSK, BMY, TSVT, LEGN
Executed On: Jan 06, 2022 at 03:00 PM EST

Expired Projects (GSK)

Discussing DVAX' HEPLISAV-B vaccine and market potential post approval
Tickers: DVAX, GSK
Execute By: Dec 08, 2017
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016

Upcoming & Overdue Catalysts (GSK)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (GSK)

ViiV Healthcare's three-year data on cabotegravir and rilpivirine regimen in mid-stage Phase 2b HIV study released
Tickers: VIIV HEALTHCARE, GSK
Occurred on: Oct 29, 2018
IPF: Inhaled αvβ6 inhibitor Phase IIa anticipated to start in 2018
Ticker: GSK
Occurred on: Sep 21, 2018
FDA rejects Glaxo's (GSK) Nucala in COPD, raises efficacy issues
Ticker: GSK
Occurred on: Sep 07, 2018
US FDA approves GSK's Krintafel (tafenoquine) in preventing the relapse of P. vivax malaria
Ticker: GSK
Occurred on: Jul 20, 2018
GSK 165 osteoarthritis Phase II data expected H2 2017
Ticker: GSK
Occurred on: May 22, 2018
Extended pharmacology: anti-IL5 mAb – Phase III expected to start in 2018
Ticker: GSK
Occurred on: Mar 19, 2018
Results presented from GlaxoSmithKline's (GSK) Nucala (mepolizumab) in asthma control in patients uncontrolled on Xolair (omalizumab)
Ticker: GSK
Occurred on: Mar 05, 2018
FDA approves GSK's Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
Ticker: GSK
Occurred on: Dec 12, 2017
IMPACT COPD exacerbation data expected H2 2017
Ticker: GSK
Occurred on: Sep 04, 2017
GlaxoSmithKline (GSK) Files New Drug Application in Japan for Shingrix Vaccine in the Prevention of Shingles
Ticker: GSK
Occurred on: Apr 18, 2017
GSK’s MUSCA study shows Nucala (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype
Ticker: GSK
Occurred on: Mar 06, 2017
GlaxoSmithKline (GSK) and Innovia (INVA) Report Top-line from a Non-Inferiority Study of Asthma Patients Switching from Seretide Accuhaler to Relvar Ellipta
Tickers: GSK, INVA
Occurred on: Feb 23, 2017
Viiv Healthcare Presents Results from 2 Phase 3 Studies Evaluating Dolutegravir + Rilpivirine in HIV Maintenance
Tickers: VIIV HEALTHCARE, PFE, JNJ, GSK, SGIOF
Occurred on: Dec 20, 2016
GlaxoSmithKline (GSK) files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
Ticker: GSK
Occurred on: Dec 02, 2016
GlaxoSmithKline (GSK) announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Ticker: GSK
Occurred on: Nov 25, 2016
GlaxoSmithKline (GSK) Expects to File Canadian Biologics License Application (BLA) for Shingrix Vaccine in the Prevention of Shingles in 2016
Ticker: GSK
Occurred on: Nov 25, 2016
GlaxoSmithKline (GSK) starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
Ticker: GSK
Occurred on: Nov 24, 2016
GlaxoSmithKline (GSK) announces phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis
Ticker: GSK
Occurred on: Nov 23, 2016
GlaxoSmithKline's (GSK) Influenza Vaccine FluLaval Quadrivalent Approved by FDA for Expanded Use in Children Ages Six Months and Older
Ticker: GSK
Occurred on: Nov 21, 2016
GSK plans to file its NDA seeking approval of its triple combination therapy for the treatment of chronic obstructive pulmonary disease (COPD) by the end of 2016
Ticker: GSK
Occurred on: Nov 21, 2016
GSK announces positive results in fourth consecutive pivotal trial of Benlysta (belimumab) in SLE
Ticker: GSK
Occurred on: Nov 13, 2016
FDA Approves Propeller Health's Platform for use with GlaxoSmithKline's (GSK) Dry Powder Inhaler Ellipta in Patients with Asthma
Tickers: PROPELLER HEALTH, GSK, HKMPF, SFE, SR One, MMM, Social Capital
Occurred on: Nov 07, 2016
Regeneron (REGN) and Sanofi's (SNY) Sarilumab for Rheumatoid Arthritis Granted PDUFA date of October 30, 2016 by FDA
Tickers: REGN, JNJ, SNY, GSK
Occurred on: Oct 28, 2016
GlaxoSmithKline (GSK) Files FDA Biologics License Application (BLA) for Shingrix Vaccine in the Prevention of Shingles
Ticker: GSK
Occurred on: Oct 24, 2016
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Plan to Submit Application to FDA in 2016 for Sirukumab in Rheumatoid Arthritis
Tickers: GSK, REGN, SNY, JNJ
Occurred on: Sep 23, 2016
GlaxoSmithKline (GSK) Announces Release of Phase 3 Results for Shingles Vaccine ZOE-70 in New England Journal of Medicine (NEJM)
Ticker: GSK
Occurred on: Sep 15, 2016
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Submit Sirukumab in Treatment of Rheumatoid Arthritis to European Medicines Agency
Tickers: GSK, JNJ, SNY, REGN
Occurred on: Sep 12, 2016
'Real world’ data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme
Ticker: GSK
Occurred on: Sep 05, 2016
GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
Ticker: GSK
Occurred on: Sep 04, 2016
NEJM publishes results of GSK’s long-term LABA safety study of Advair Diskus in children aged 4-11 years with asthma
Ticker: GSK
Occurred on: Sep 01, 2016
FDA Approves FLONASE Sensimist Allergy Relief
Ticker: GSK
Occurred on: Aug 03, 2016
Phase 1b trial data of FP-1039 to be presented at American Society of Clinical Oncology (ASCO) 2016, if Arm C full data wil be positive, FPRX will seek to regain rights for FP-1039 in the U.S., Canada and the E.U. from GSK
Tickers: FPRX, GSK
Occurred on: Jun 20, 2016
New Phase III data shows greater treatment response with GSK’s Benlysta (belimumab) vs placebo in patients with highly active SLE
Ticker: GSK
Occurred on: Jun 08, 2016
GSK announces phase III study of sirukumab meets both co-primary endpoints in patients with rheumatoid arthritis
Ticker: GSK
Occurred on: Jun 08, 2016
StrimvelisTM receives European marketing authorisation to treat very rare disease, ADA-SCID
Ticker: GSK
Occurred on: May 27, 2016
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
Ticker: GSK
Occurred on: May 25, 2016
Initial Results Expected from Phase 3 Lung Function Study for COPD
Tickers: INVA, GSK
Occurred on: May 24, 2016
5 arrested for alleged theft of trade secrets from GlaxoSmithKline (GSK) and Five Prime Therapeutics (FPRX), including data related to FP-1039
Tickers: GSK, FPRX
Occurred on: Jan 20, 2016

Strategic Initiatives (GSK)

GlaxoSmithKline (GSK) will collaborate with public/private group, the Coalition for Epidemic Preparedness Innovations (CEPI) to help develop a vaccine against 2019-nCoV
Ticker: GSK
Announcement Date: Feb 03, 2020
GlaxoSmithKline (GSK) and VBI Vaccines (VBIV) Enter Research Collaboration to Evaluate VBIV's LPV Platform
Tickers: GSK, VBIV
Announcement Date: Feb 09, 2016
Valneva Signs New R&D Collaboration with GlaxoSmithKline for the EB6 Cell Line; Advanced Development program sponsored by the US Department of Health and Human Services; Valneva to receive research fees under the new agreement
Tickers: VLA.PA, GSK
Announcement Date: Feb 08, 2016

GSK Overview